Evkeeza
Payments companies reported to CMS as associated with Evkeeza. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Evkeeza, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Evkeeza
These are the largest totals companies reported as associated with Evkeeza. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| James Underberg | New York, NY | Internal Medicine | $216,625.68 |
| Matthew Budoff | Torrance, CA | Cardiovascular Disease | $147,622.54 |
| Alan Brown | Naperville, IL | Cardiovascular Disease | $66,695.39 |
| Michael Wilkinson | San Diego, CA | Cardiovascular Disease | $54,551.69 |
| Deepak Talreja | Virginia Beach, VA | Interventional Cardiology | $50,579.86 |
| John Isaac | Houston, TX | Interventional Cardiology | $35,956.72 |
| James Trippi | Indianapolis, IN | Cardiovascular Disease | $34,817.69 |
| Eliot Brinton | Salt Lake City, UT | Endocrinology, Diabetes & Metabolism | $34,555.19 |
| Norman Lepor | Beverly Hills, CA | $28,148.43 | |
| Nicole Ciffone | Tucson, AZ | Acute Care (Nurse Practitioner) | $24,673.36 |
Prescribed Evkeeza?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.